Cwm LLC Grows Position in Twist Bioscience Co. (NASDAQ:TWST)

Cwm LLC raised its position in Twist Bioscience Co. (NASDAQ:TWST) by 141.9% in the third quarter, Holdings Channel reports. The fund owned 5,894 shares of the company’s stock after buying an additional 3,457 shares during the period. Cwm LLC’s holdings in Twist Bioscience were worth $266,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its position in shares of Twist Bioscience by 34.8% during the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock worth $5,895,000 after purchasing an additional 44,349 shares during the last quarter. SageView Advisory Group LLC acquired a new position in shares of Twist Bioscience during the 1st quarter worth about $1,144,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Twist Bioscience in the 1st quarter valued at about $300,000. Sei Investments Co. increased its holdings in shares of Twist Bioscience by 32.7% in the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock valued at $7,670,000 after acquiring an additional 55,124 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC raised its position in shares of Twist Bioscience by 38.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after acquiring an additional 37,376 shares in the last quarter.

Analysts Set New Price Targets

TWST has been the subject of a number of research analyst reports. The Goldman Sachs Group upped their price target on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Leerink Partners increased their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Evercore ISI lifted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird upped their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

Insider Buying and Selling

In related news, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the sale, the chief financial officer now directly owns 73,397 shares in the company, valued at $3,068,728.57. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, COO Patrick John Finn sold 2,885 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $115,198.05. Following the sale, the chief operating officer now directly owns 168,327 shares of the company’s stock, valued at approximately $6,721,297.11. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Laponis sold 856 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the sale, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,039 shares of company stock valued at $1,704,396 over the last ninety days. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $45.35 on Tuesday. The stock has a market cap of $2.64 billion, a P/E ratio of -13.50 and a beta of 1.77. Twist Bioscience Co. has a 1-year low of $14.42 and a 1-year high of $60.90. The firm has a fifty day moving average price of $44.03 and a 200 day moving average price of $44.55.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The company had revenue of $81.50 million for the quarter, compared to analysts’ expectations of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The firm’s revenue was up 27.7% on a year-over-year basis. During the same period in the prior year, the company earned ($1.01) earnings per share. Sell-side analysts expect that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.